Patrick LEGEMBRE
  • E-mail :[email]
  • Phone : 0223237241
  • Location : RENNES, France
Last update 2017-03-05 17:33:42.818

Patrick LEGEMBRE PhD Onco-Immunology

Course and current status

Patrick Legembre

42 years, Born in Evry (France), French.

Present address:

  • CLCC Eugène Marquis; Inserm U1242; Batiment D, 1er étage, Rue Bataille Flandres-Dunkerque. 35042 RENNES.
  • Phone: (+33)-2-2323-7241;
  • E-mail: patrick.legembre@inserm.fr
  • Web Site: http://oss-clcc-rennes.com/research/group1/about.html
  • Key works: Apoptosis, Death receptors, migration, calcium, cell signaling, chemotherapy resistance. 

EDUCATION

  • 2007- Habilitation to supervise research (HDR); University of Bordeaux; Immunology/Oncology.
  • 2002- Ph.D. degree; University of Bordeaux; Immunology/Oncology.

EMPLOYMENT

  • Jan 2017- now: Deputy Director U1242, Chemistry Oncogenesis Stress & Signaling (COSS), Ligue Contre Le cancer Team.
  • Jan 2015- Dec 2016- Director Inserm ER440. Ligue Contre Le cancer Team. Rennes/France.
  • Jan 2010-Dec 2014- Senior researcher (Director of Research) INSERM. U1085. Ligue Contre Le cancer team. Rennes/France.
  • Dec 2005-Dec 2009- Researcher (CR INSERM). UMR CNRS 5164 (Pr. Moreau JF). Bordeaux/France.
  • Sept 2002-Oct 2005- Postdoctoral fellow, (Pr Peter M). Ben May Institute For Cancer Research/ University of Chicago. Chicago/USA.

PATENTS

WO2010/063847; WO2014118317; WO2015189236; WO2015044229; WO2015158810; WO2015104284

Scientific Academy Society and committees membership

  • Member of National Ligue Contre Le Cancer Scientific Council (2013-2017)
  • Member of National INSERM scientific council-CSS2 (2008-2012)
  • Associate editor of the journal Recent Patents on Anti-Cancer Drug Discovery. (2009-Present)
  • Member of the Editorial Board of the journal Anti-Cancer Drugs. (2010-Present)

Honors and Awards

  • 2016: Price “Ruban Rose Avenir”.
  • 2016: Price “Fondation Banque Populaire de l’Ouest Avenir”.
  • 2012-2017: Equipe “Ligue Contre Le Cancer”.
  • 2007-2012: ANR young scientist.

RESEARCH & PUBLICATIONS (5 most relevant over 50 publications)/ h-index:18

  1.  Poissonnier A, Sanséau D, Le Gallo M, Malleter M, Levoin N, Viel R, Morere L, Penna A, Blanco P, Dupuy A, Poizeau F, Fautrel A, Seneschal J, Jouan F, Ritz J, Forcade E, Rioux N, Contin C, Ducret T, Vacher A-M, Barrow PA, Flynn RJ, Vacher P, and Legembre P. Immunity. 2016.              
  2. Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouqué A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Ségui B, Legembre P. Oncogene. 2015.
  3. Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Leveque J, Jezequel P, Campion L, Campone M, Ducret T, Macgrogan G, Debure L, Collette Y, Vacher P, Legembre P. Cancer Res. 2013.
  4. Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, Ségui B, Levade T, Vacher AM, Reiffers J, Ducret T, Moreau JF, Cahalan MD, Vacher P, Legembre P. PNAS. 2011. 
  5. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, Blanco P, Le Seyec J, Ducret T, Counillon L, Moreau JF, Hofman P, Vacher P and Legembre P. PLoS Biology. 2011.

CONFERENCE ORGANIZATION

Co-organizer of International Congress “Cancer Cell Death and Therapy 2017”, St. Malo (France), May 10-12, 2017.

Co-organizer of 1st International Congress “Cell Death in Cancer”, St. Malo (France), May 13-16, 2012.

 

Scientific summary

CD95 (also known as Fas) is considered as a death receptor and it belongs to the TNF (tumor necrosis factor) receptor family. Its ligand, CD95L is a transmembrane cytokine (m-CD95L), which can be cleaved by metalloproteases and released in bloodstream as a soluble fragment (cl-CD95L). While m-CD95L is found at the surface of immune cells where it orchestrates the elimination of transformed/infected cells and the immune contraction, cl-CD95L behaves as a proto-oncogene enhancing the risk of metastatic occurrence in breast cancers. Our main goals are to decipher i) how CD95 switches from implementing cell death to non-apoptotic signaling pathways and ii) what are the cells whose function is deregulated by the naturally processed ligand in breast cancers.

Image d’exemple